Back to Browse Journals » Orphan Drugs: Research and Reviews » Volume 2

Betaine treatment of cystathionine β-synthase-deficient homocystinuria; does it work and can it be improved?

Authors Maclean KN

Received 6 July 2012

Accepted for publication 14 August 2012

Published 28 September 2012 Volume 2012:2 Pages 23—33


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Kenneth N Maclean

Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA

Abstract: Inactivating mutations in cystathionine β-synthase result in classical homocystinuria (HCU) and are typically accompanied by severe elevations of plasma and tissue homocysteine, methionine, S-adenosylmethionine, S-adenosylhomocysteine and significantly decreased cysteine. HCU is usually accompanied by marfanoid skeletal abnormalities, osteoporosis, ectopia lentis and/or severe myopia, cognitive impairment, and a dramatically increased incidence of atherosclerosis and thromboembolic complications of variable presentation. If untreated, HCU is a serious life-threatening disease. Betaine (N,N,N-trimethylglycine) is a zwitterionic quaternary ammonium compound that can lower homocysteine, S-adenosylmethionine, S-adenosylhomocysteine, and increase cysteine in HCU by serving as a methyl donor for the remethylation of homocysteine in a reaction catalyzed by betaine–homocysteine S-methyltransferase. This review considers the clinical efficacy and safety of betaine treatment of HCU. Possible strategies by which the efficacy of this treatment might be improved are discussed.

Keywords: homocystinuria, homocysteine, betaine, cystathionine beta-synthase, betaine–homocysteine S-methyltransferase

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

The instability of the flax element LIS-1 in transgenic Arabidopsis thaliana

Bastaki NK, Cullis CA

Research and Reports in Biology 2015, 6:89-105

Published Date: 14 May 2015

Recent insights into the pathophysiology of mTOR pathway dysregulation

Gitto SB, Altomare DA

Research and Reports in Biology 2015, 6:1-16

Published Date: 29 January 2015

Novel tumor markers in the serum of testicular germ cell cancer patients: a review

Syring I, Müller SC, Ellinger J

Current Biomarker Findings 2014, 4:133-137

Published Date: 9 September 2014

HIV treatment: mechanisms of neurotoxicity and implications for targeted therapy

Wu C, Lu Y

Neurobehavioral HIV Medicine 2012, 4:75-98

Published Date: 4 September 2012

The impact of hypoxia on oncolytic virotherapy

Guo ZS

Virus Adaptation and Treatment 2011, 3:71-82

Published Date: 16 November 2011

Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection

Rampling T, Nelson M

Virus Adaptation and Treatment 2011, 3:25-34

Published Date: 25 March 2011

Duchenne muscular dystrophy gene therapy: Lost in translation?

Dongsheng Duan

Research and Reports in Biology 2011, 2:31-42

Published Date: 4 March 2011